Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.30 |
| ▸ | HRH1 | P35367 | 4/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.30 |
| ▸ | HTR2A | P28223 | 3/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6214256 | 0.82 | RPS6KA5 (0.37) | SLC6A2SLC6A4SLC6A3TDP1PIN1 | |
| SCHEMBL4089463 | 0.73 | METAP1 (0.40) | SLC6A2SLC6A4SLC6A3TDP1KCNA5 | |
| SCHEMBL6215293 | 0.72 | MAPT (0.33) | TSHRMAPT | |
| SCHEMBL1131039 | 0.71 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3KCNA5TSHR | |
| SCHEMBL2368819 | 0.71 | CHRM4 (0.36) | CHRM4 | |
| SCHEMBL6212769 | 0.71 | ALDH1A1 (0.32) | TSHR | |
| Methane SCHEMBL28543758 | 0.69 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3KCNA5TSHR | |
| Hydrochloric Acid SCHEMBL6775513 | 0.69 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3KCNA5TSHR | |
| SCHEMBL6204712 | 0.67 | ABL1 (0.33) | MEN1KMT2AABL1BCR | |
| SCHEMBL22964601 | 0.67 | ABL1 (0.37) | MEN1KMT2AABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578732-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | PFIZER INC | 2004-11-04 | — | — | US | disclosed |
| WO-2004056786-A2 | PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | CCNA1, CCNB1, CCNT1 | SLC6A2 3530/4885SLC6A4 3947/4885SLC6A3 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.